A rare opportunity to acquire the only fully built, clinically validated, FDA-registered at-home vision diagnostics platform shipping at scale. A 29-patent portfolio pairs with proprietary, MIT-licensed optical technology and a HIPAA-compliant telehealth network that delivers prescriptions across 40 U.S. states. Over 50,000 devices sold in 150+ countries over eight years of commercial operation - with zero product defects, zero MDRs, and zero product litigation throughout the entire history of the business.

This is a continuation of the commercialization play, not a speculative technology-development bet.

More than $31 million has been invested to date for software and product development, inventory, and marketplace testing.

WHY THIS IS EXCEPTIONAL
◉ Patented, smartphone-based vision diagnostics platform - test vision, measure refractive error, and obtain prescriptions remotely.
◉ Exclusive license to MIT inverse Shack-Hartmann refraction technology — the foundational science behind the platform.
◉ 29-patent portfolio (granted plus pending) covering smartphone diagnostics, optical measurement, automated vision tracking, and PD measurement.
◉ Seven FDA-registered medical devices and apps - refraction, visual acuity, contrast, color, Amsler, PD, and reading-numbers measurement.
◉ Full compliance stack: ISO 13485, ISO 9001, HIPAA, and a state medical device manufacturer license - a five-cert posture few digital-health platforms hold at once.
◉ Four registered clinical trials on ClinicalTrials.gov, including a non-inferiority study versus phoropter and autorefractor, plus multiple CES Innovation Awards and a 2020 Frost Radar award.
◉ Blue-chip B2B relationships — including a national pharmacy chain, a major health system, and a leading online eyewear retailer (founded by the company's own co-founder).
◉ Proprietary longitudinal vision dataset across the deployed fleet - a substrate for AI-driven diagnostics, predictive care, and population-health analytics.
◉ Substantial finished-goods inventory plus contract-manufacturing relationships in place - supporting immediate scale with no manufacturing lead-time exposure.
◉ Clean financial posture: no debt, no loans, capital on hand, and a prior $25M strategic asset transaction demonstrating realized value in the IP.

THE UPSIDE FOR STRATEGIC AQUIRER
The platform is fully developed but deliberately under-commercialized - the remaining work is commercial scale, not technology build-out. Multiple paths to value creation:
◉ Scale direct-to-consumer adoption and conversion from testing to prescription to eyewear purchase.
◉ Build recurring revenue — vision-tracking subscriptions and Rx renewal services across the installed base.
◉ Expand B2B partnerships with optical retailers, clinics, telehealth platforms, and pharmacies.
◉ Monetize the proprietary dataset for AI diagnostics and predictive care.
◉ Expand into global and underserved markets where low-cost remote diagnostics travel well.

NDA is required to secure the comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.